Stock analysts at Maxim Group started coverage on shares of Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) in a report released on Friday, Benzinga reports. The brokerage set a “buy” rating and a $1.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 313.22% from the stock’s previous close.
Silexion Therapeutics Stock Performance
Shares of NASDAQ SLXN opened at $0.24 on Friday. Silexion Therapeutics has a 1 year low of $0.23 and a 1 year high of $4.65. The company’s 50-day moving average is $0.67.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported ($5.87) earnings per share for the quarter.
Silexion Therapeutics Company Profile
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Featured Articles
- Five stocks we like better than Silexion Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- Battle of the Retailers: Who Comes Out on Top?
- Investing in Commodities: What Are They? How to Invest in Them
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.